


# Aganitha Launches Igniva™: A Suite of AI Agents for Therapeutic Design and Research

*Igniva™ advances biopharma R&D with reasoning & explainability focused AI. Networked AI agents equip researchers with broader, deeper scientific insights*

SANTA CLARA (PMWC 2025), CA, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- [Aganitha](#) Launches Igniva™: A Suite of AI Agents for Therapeutic Design and Research

- \* Igniva™ advances therapeutic research and precision medicine with reasoning & explainability focused AI
- \* Networked AI agents collaborate to refine hypotheses and accelerate decisions
- \* Suite enables holistic decision-making by equipping researchers with broader, deeper scientific insights



Announced at PMWC 2025 – Aganitha announces the launch of Igniva™, a suite of AI agents designed to advance therapeutic research and precision medicine across multiple disease areas. This suite integrates and enhances Aganitha's innovations for R&D, applied successfully over the past several years at global pharma and biotech organizations .

## Addressing Challenges in Therapeutic Development

The complexity of drug discovery, the integration of multi-modal data, and the need for efficient regulatory pathways pose significant hurdles in biopharma. Igniva™ is designed to accelerate the journey from data to actionable insights, bridging the gaps between research, development, and clinical application.

## What is Igniva™?

Igniva™ makes the latest advances in deep science and deep tech accessible to researchers. It does so by analyzing and reasoning over biological, chemical, and clinical datasets, knowledge bases, and computational & AI models, all with human experts in the loop.



AI adoption in biopharma is no longer optional. Igniva™ equips researchers with the tools for broader, deeper scientific insights, keeping them ahead in a rapidly evolving landscape with Agentic AI."

*Vikram Duvvoori, co-founder  
and CEO of Aganitha*

### Key Capabilities & Innovations

The Igniva™ suite incorporates cutting-edge technologies to drive therapeutic innovation:

- \* Foundational Models for Biology & Chemistry
- \* Advancements in High-Throughput Biology & Chemistry Experimentation
- \* Multi-Modal AI Integrating Molecular, Imaging, and Clinical Insights
- \* GenAI-Driven Therapeutic Design & Optimization
- \* Quantum Chemistry Feature-Driven Models for Characterization and Optimization of Therapeutic

### Candidates

- \* LLM-Powered Compliance and Regulatory Workflows

### How Igniva™ Works

These cognitive agents collaborate through multi-agent orchestration, dynamically analyzing biological and chemical data, generating insights, and refining hypotheses, all with human expertise providing feedback. The suite is modular, scalable, and continues to expand.

### The Network Effect: How Agents Collaborate

A key feature of Igniva™ is its network effect. Agents are grouped into foundational, domain-specific, and role-based categories, such as coaches and hypothesis generators. This interconnected structure enhances collaboration among agents: allowing them to share insights, refine predictions, and improve decision-making efficiency across different stages of therapeutic development.

### Why This and Why Now

"AI adoption in biopharma is no longer optional—it's critical. The race to first-in-class and best-in-class therapies demands faster, smarter, and more holistic decision-making. Igniva™ equips researchers with the tools to leverage broader, deeper scientific insights, accelerating breakthroughs and keeping them ahead in a rapidly evolving landscape", said Vikram Duvvoori, co-founder and CEO of Aganitha.

Explaining the significance of this announcement, Mr. Prasad Chodavarapu, co-founder and MD of Aganitha explained: "Igniva™ brings a new level of reasoning and explainability to AI-driven therapeutic research. Its multi-scalar systems biology and physics-informed chemistry methods enable a deeper understanding of disease mechanisms and drug interactions. By providing interpretable insights, Igniva™ supports researchers in designing and optimizing therapeutics with greater confidence and efficiency".

## Join the Future of AI-Assisted R&D

Aganitha invites stakeholders in the biopharma industry to explore Igniva™ and its role in AI-assisted therapeutic discovery and development.

For media inquiries, please contact: [media@aganitha.ai](mailto:media@aganitha.ai)

### About Aganitha

Aganitha partners with global biopharma to bring better medicines to market faster with AI-assisted solutions. We make AI work for Science. Our expertise spans physics-based chemistry, omics-enriched biology, computational sciences, and generative AI-powered drug drug design. We drive innovation across multiple disease areas.

For media inquiries, please contact:

Aganitha AI, Inc.

[media@aganitha.ai](mailto:media@aganitha.ai)

Vikram Duvvoori

Aganitha AI

+1 408-898-2432

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/782695657>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.